Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

Premium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

JNJ aims to produce 600-900 million doses of its pending cure by the end of Q1-2021. The pharma giant has invested over US$1 billion in partnership with Washington to co-fund vaccine research. Phase I trials are intended for September. If all goes right, JNJ plans to produce at least one billion doses annually. I stress the word “pending,” because JNJ's vaccine is still in development and is not a done deal. However, credit JNJ for beginning research back in January this year. The company has identified a leading vaccine candidate and two backups. I sincerely hope they deliver on their promises. Definitely keep an eye on JNJ's progress. Analysts including Brian Acker and Paul Harris have enough faith in JNJ to recommend it as a top pick during this pandemic. JNJ pays a 2.56% dividend and trades at 16.7x earnings. It's a stable stock and has recovered from the late-March market plunge to return to previous high around $150. It's stable and its range of health and personal care products will remain in consistent demand during post-lockdown. Of course, if JNJ develops a vaccine, shares will skyrocket.

BUY

An excellent company and raised its dividend 55 years in a row. It has done a fantastic job and is a diversified healthcare stock. They have benefited from COVD-19. It is one of the better companies. This gets is whole-hearted support right now.

TOP PICK

He would be a buyer here as it has dropped so much from the last time he recommended it. They announced they have something related to COVID-19 vaccination and can start human trials in late September. (Analysts’ price target is $157.85)

TOP PICK

Defensive. One of the largest healthcare companies in the world. Medical devices, pharma, personal care products. Great story. Consistent dividend grower. Talcum litigation issue has been dealt with. Very stable company. Yield is 3.03%. (Analysts’ price target is $159.84)

TOP PICK

It's been sideways for a couple years. This week, it shot down but he believes it will get back out to where it was before. It can definitely break out after recovery. They have more divisions than just pharma, like pet items. (Analysts’ price target is $160.28)

TOP PICK

Model price is $182.97 or 28% upside. He likes the company and thinks it has good upside. (Analysts’ price target is $160.28)

PAST TOP PICK

(A Top Pick Dec 16/19, Up 2%) A defensive name but durable. You're paid to wait. This applies to his other two past picks today, too.

PAST TOP PICK

(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.

BUY

Has long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.

TOP PICK

His model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)

TOP PICK

In an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)

BUY

Given the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.

BUY

SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.

TOP PICK

Breaking news: found not guilty of misleading the public with its baby powder. A behemoth, well-diversified trading at an attractive 16x earnings and 5% free cash flow yield. A defensive name today. (Analysts’ price target is $150.28)

TOP PICK

If you look at the aggregate liabilities of the talcum powder legal issue, the market has over-estimated the impact on the company, he believes. The litigation could be on-going for years to come and the time value of money works in their favour. Yield 2.69% (Analysts’ price target is $150.28)

Showing 181 to 195 of 626 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)

It's a Monthly Gems opinion which is available only for Stockchase Premium